Pragma Bio is searching for cancer treatments hidden in our microbiome
The infusion of funding reflects our goal of unveiling the symbiotic relationship between nature and the human body, enabling us to create natural medicines that foster our well-being
The participation of world-class healthcare investors is a validation of our approach, which is aimed at uncovering medicines naturally produced within our bodies every day. Patients are waiting for better options, and Pragma Bio will offer them
Kareem Barghouti CEO of Pragma Bio
Congrats to the team at Pragma Bio for its latest 10M round of financing to expand its proprietary VBx1 technology platform — an end-to-end pipeline encompassing genomic sequencing, artificial intelligence, and synthetic biology — to discover novel therapeutics for cancer treatments.
We are so honored to be investing alongside Viking Global, Merck Global Health Innovation, CJ Investments, and The Venture Collective.
I first met with Kareem Barghouti Peter McCaffrey, and Ayin Vala at the 2019 JPMorgan Healthcare Conference. I still remembered that they were passionately explaining how AI can transform microbiome drug discovery With its proprietary access to patient data from the Texas Medical Center, the Pragma team was able to demonstrate success in validating its approach to sourcing drugs from the microbiome.
As one of the earliest investors in Pragma, I can’t be more proud of what the team has achieved.